Skip to main content
Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News FAQ
On This Report

Cholera Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Type, Distribution Channel, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11898| Published Date: Jun-2026| Format: PDF, Excel
Market Outlook

Market Size and Growth Outlook

Cholera Vaccines Market size was around USD 110.1 million in 2026 and is slated to grow at a 9.5% CAGR from 2027 to 2036, attaining USD 272.85 million by 2036. The industry revenue for 2027 is estimated at USD 118.91 million.

Base Year Value (2026)
USD 110.1 million
CAGR (2027-2036)
9.5%
Forecast Year Value (2036)
USD 272.85 million
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036

Get more details on this report

Request Free Sample Report
Snapshot

Cholera Vaccines Market Intelligence Snapshot

Regional Market Dynamics

  • North America holds 39.86% share due to strong procurement systems, advanced public health infrastructure, and coordinated vaccine distribution and preparedness frameworks.
  • Asia Pacific grows at 11.31% CAGR due to higher outbreak exposure, expanding immunization campaigns, and increasing preventive vaccination in vulnerable populations.

Segment Momentum

  • Killed Oral O1 and O139 held a 63% market share in 2026 due to their suitability for large-scale immunization programs, with oral delivery supporting efficient deployment and broad coverage across target populations.
  • Retail pharmacy is growing fastest because it expands community-level vaccine access, offering greater convenience and supporting broader distribution beyond hospital-centered immunization pathways.

Market Expansion Drivers

  • Increasing cholera outbreak awareness boosting vaccination programs in endemic regions.
  • Expanding global travel and NGO-led immunization campaigns driving vaccine demand.
  • WHO elimination targets and technology transfer initiatives expanding vaccine production capacity.

Leading Market Participants

  • Major players in the cholera vaccines market include Sanofi S.A. (France), Valneva SE (France), EuBiologics Co., Ltd. (South Korea), Bharat Biotech International Ltd. (India), Serum Institute of India Pvt. Ltd. (India), Emergent BioSolutions Inc. (United States), Incepta Vaccine Ltd. (Bangladesh), Vabiotech (Vietnam), PT Bio Farma (Persero) (Indonesia), Shantha Biotechnics Pvt. Ltd. (India).

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

  • 2026 Market Size: USD 110.1 million
  • 2027 Estimated Market Size: USD 118.91 million.
  • Projected Market Size: USD 272.85 million by 2036
  • Growth Forecast: 9.5% CAGR (2027-2036)

Regional and Segment Outlook

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Killed Oral O1 and O139 (Type) | Hospital Pharmacy (Distribution Channel) | Dukoral (Product)
  • Emerging Opportunity Segment: Killed Oral O1 and O139 (Type) | Retail Pharmacy (Distribution Channel) | Vaxchora (Product)
Market Dynamics

Market Growth Drivers and Industry Trends

Increasing cholera outbreak awareness boosting vaccination programs in endemic regions

Greater awareness of recurring cholera outbreaks is encouraging public health authorities to strengthen preventive vaccination activities, thereby supporting the cholera vaccines market. Outbreak preparedness has become increasingly important in areas where inadequate sanitation, unsafe water supplies, displacement, and climate-related disruptions can increase exposure to cholera. Awareness of the health and economic consequences associated with outbreaks encourages governments and health organizations to incorporate vaccination into broader prevention and response programs. Targeted immunization campaigns can also help protect vulnerable populations in areas experiencing recurring transmission, particularly when vaccination is combined with improvements in water, sanitation, and hygiene measures.

Expanding global travel and NGO-led immunization campaigns driving vaccine demand

International movement of people and humanitarian activities are increasing the need for coordinated disease-prevention measures, which will drive the cholera vaccines market growth in regions exposed to transmission risks. Travelers, displaced populations, and communities affected by humanitarian emergencies can face elevated exposure where sanitation infrastructure is limited, creating requirements for targeted immunization and outbreak preparedness. Non-governmental organizations and other humanitarian groups play an important role in supporting vaccination campaigns in vulnerable communities, particularly during emergencies and disease-control initiatives. Broader coordination between public health programs and humanitarian organizations is facilitating vaccine deployment where conventional healthcare access may be constrained.

WHO elimination targets and technology transfer initiatives expanding vaccine production capacity

Global disease-control objectives are encouraging investments in vaccine manufacturing capabilities and strengthening the cholera vaccines market. International efforts focused on reducing cholera transmission are increasing attention toward reliable vaccine availability, supply resilience, and production scalability. Technology transfer initiatives can support the development of manufacturing expertise in additional regions, allowing producers to strengthen local or regional vaccine capabilities and reduce dependence on limited production sources. Greater collaboration around manufacturing processes, technical knowledge, and quality requirements is also helping expand the capacity needed to support vaccination programs during routine prevention activities and emergency outbreak responses.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Increasing cholera outbreak awareness boosting vaccination programs in endemic regions 2.20% High Africa, Asia Pacific High Near Term
Expanding global travel and NGO-led immunization campaigns driving vaccine demand 1.90% High Global High Near Term
WHO elimination targets and technology transfer initiatives expanding vaccine production capacity 1.70% High Asia Pacific, Africa High Mid Term
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Regional Forecast

Regional Demand Dynamics

Cholera Vaccines Market
Largest Region
North America
39.86% Market Share in 2026

North America (Largest Region)

In the cholera vaccines market, North America held the largest share at 39.86% in 2026, reflecting advanced healthcare infrastructure, strong public health capabilities, and established access to preventive vaccination services. The region benefits from sophisticated disease surveillance and preparedness systems that support the procurement and deployment of vaccines when infection risks emerge. Greater awareness of infectious disease prevention, combined with well-developed regulatory and healthcare frameworks, also contributes to sustained demand for vaccines targeting cholera and other enteric diseases.

Asia Pacific (Fastest-Growing Region)

Asia Pacific is experiencing the fastest growth in the cholera vaccines market, supported by the presence of areas with elevated vulnerability to waterborne diseases, expanding immunization infrastructure, and increasing emphasis on public health preparedness. Improvements in healthcare access and disease surveillance are enabling more effective prevention strategies, while government and public health initiatives are strengthening vaccination coverage in at-risk populations. Growing investment in sanitation, healthcare delivery, and infectious disease control further supports regional demand for cholera vaccines.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
Country Insights

Key Country Insights

Germany 🇩🇪

Quality Manufacturing Focus

Germany supports the cholera vaccines market through advanced pharmaceutical manufacturing standards and investments in vaccine quality and regulatory compliance. German organizations also participate in collaborative research and international health programs that strengthen vaccine availability.

France 🇫🇷

Humanitarian Vaccine Support

France maintains a strong focus on cholera vaccines through public health collaborations and participation in international immunization initiatives. French organizations contribute to vaccine research and procurement activities that reinforce access for outbreak response programs.

Italy 🇮🇹

Collaborative Research Network

Italy advances the cholera vaccines market through academic research, vaccine development partnerships, and public health collaboration. Italian institutions continue supporting projects that improve vaccine production processes and strengthen preparedness for infectious disease management.

Japan 🇯🇵

Public Health Preparedness

Japan prioritizes vaccine development technologies and preparedness strategies that strengthen responses to infectious disease risks. Japan also supports cholera vaccine research through partnerships focused on improving formulation quality and supply reliability for international health programs.

South Korea 🇰🇷

Biopharmaceutical Expansion

South Korea is strengthening its cholera vaccines market through investments in modern vaccine manufacturing infrastructure and biotechnology capabilities. South Korean companies continue expanding production expertise while supporting regional and global vaccine supply partnerships.

United States 🇺🇸

Global Supply Innovation

The U.S. emphasizes vaccine research, manufacturing capacity, and international procurement partnerships that support cholera immunization programs. U.S.-based organizations continue to prioritize product innovation and scalable production for public health and humanitarian vaccination initiatives.

Segment Analysis

Segment Leadership and Growth Trends

Cholera Vaccines Market Share (%), by Type, 2026

Killed Oral O1 and O139
Whole Cell v. Cholerae O1 with Recombinant B- subunit

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Type Segment Analysis: Killed Oral O1 and O139 (Largest & Fastest-Growing Segment)

The killed oral O1 and O139 segment accounted for 63% share of the cholera vaccines market in 2026 and represented both the largest and fastest-growing vaccine type. Its position is supported by the importance of oral vaccination approaches in cholera prevention, particularly in settings where controlling transmission requires practical and scalable immunization strategies. The ability to target the O1 and O139 serogroups, which are associated with cholera disease, strengthens the relevance of this vaccine type in public health programs. Continued emphasis on outbreak preparedness, preventive vaccination, and access to effective cholera control measures supports sustained demand for this segment.

Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)

Hospital pharmacy held the largest share of the cholera vaccines market in 2026 at 48.23%, reflecting the important role of healthcare institutions in vaccine administration, disease prevention, and public health response. Hospital-based distribution provides access to trained healthcare personnel and established vaccination infrastructure, making it particularly relevant for populations requiring organized immunization services. Its role is further supported by the need for coordinated vaccine delivery during disease-control initiatives and in areas facing elevated cholera risks.

Retail pharmacy is the fastest-growing distribution channel as vaccination access increasingly expands beyond traditional hospital settings. Retail-based availability can improve convenience and accessibility for individuals seeking preventive immunization while supporting broader community-level vaccine delivery. The growing emphasis on decentralized healthcare services and easier access to preventive products is creating additional opportunities for pharmacies to participate in vaccine distribution.

Segment Sub-Segment Largest Segment Fastest Growing
Type Whole Cell V. Cholerae O1 with Recombinant B- Subunit, Killed Oral O1 and O139 Killed Oral O1 and O139 Killed Oral O1 and O139
Distribution Channel Hospital Pharmacy, Retail Pharmacy, Other Hospital Pharmacy Retail Pharmacy
Product Vaxchora, Dukoral, Shanchol, Others Dukoral Vaxchora
Read our Research Approach →
Competitive Landscape

Competitive Landscape and Market Positioning

Prominent players in the cholera vaccines market:

1. Sanofi S.A. (France)

2. Valneva SE (France)

3. EuBiologics Co. Ltd. (South Korea)

4. Bharat Biotech International Ltd. (India)

5. Serum Institute of India Pvt. Ltd. (India)

6. Emergent BioSolutions Inc. (United States)

7. Incepta Vaccine Ltd. (Bangladesh)

8. Vabiotech (Vietnam)

9. PT Bio Farma (Persero) (Indonesia)

10. Shantha Biotechnics Pvt. Ltd. (India)

The cholera vaccines market is benefiting from increased focus on public health preparedness and vaccine accessibility across high-risk regions. Collaborative research efforts are supporting advancements in vaccine stability, oral delivery systems, and long-term immunity enhancement. Greater emphasis on scalable production and immunization outreach programs is also contributing to stronger market development initiatives.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
Sanofi S.A. (France)
Valneva SE (France)
EuBiologics Co. Ltd. (South Korea)
Bharat Biotech International Ltd. (India)
Serum Institute of India Pvt. Ltd. (India)
Emergent BioSolutions Inc. (United States)
Incepta Vaccine Ltd. (Bangladesh)
Vabiotech (Vietnam)
PT Bio Farma (Persero) (Indonesia)
Shantha Biotechnics Pvt. Ltd. (India).
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Biovac Institute Apr-24 The Biovac Institute initiated clinical trials for South Africa’s first locally manufactured oral cholera vaccine following regulatory approval. This development marks a material step toward regional vaccine self-sufficiency, reducing reliance on imported supply chains and establishing a new manufacturing footprint to address demand within the African continent.
Sapigen Biologix Apr-24 Sapigen Biologix announced plans to expand its vaccine manufacturing facility in Odisha, India, with a specific focus on producing oral cholera vaccines. The investment is intended to strengthen India's domestic production capabilities, contributing to global supply resilience and diversifying manufacturing centers for critical immunization products.
EuBiologics Mar-24 EuBiologics secured WHO prequalification for its second cholera vaccine manufacturing facility in South Korea, a critical milestone for increasing global production capacity. This expansion, combined with the successful development of the Euvichol-S vaccine, is expected to enhance output volumes and optimize cost structures to address persistent global supply shortages.
African Union & French Government Mar-24 The African Union and the French Government advanced a strategic initiative to foster local vaccine manufacturing across Africa. By focusing on critical vaccines, including cholera, the collaboration aims to structurally reduce dependence on external suppliers, enhance regional manufacturing capacity, and improve long-term supply chain security for the healthcare market.
Bavarian Nordic Feb-23 Bavarian Nordic acquired the rights to the Vaxchora cholera vaccine from Emergent BioSolutions. The transaction included the transfer of manufacturing facilities in Bern, Switzerland, and San Diego, California, along with associated personnel. This acquisition significantly alters the competitive landscape by consolidating manufacturing assets and intellectual property under Bavarian Nordic’s global vaccine portfolio.
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

Cholera Vaccines Market — Custom Segments

Segment Sub-Segment
Age Group Pediatric, Adolescent, Adult
End User Government & Public Health Agencies, Hospitals & Clinics, Humanitarian Organizations
Immunization Program Routine Immunization Programs, Mass Vaccination Campaigns, Outbreak Response Programs, Travel Vaccination Programs

Cholera Vaccines Market — Custom TOC

Custom Chapter Custom Details
Global Vaccine Procurement and Tender Intelligence
  • Multilateral Procurement Landscape
  • National Tender Strategies
  • Supplier Participation and Award Trends
  • Procurement Planning Outlook
Outbreak Preparedness and Stockpile Strategy
  • Global Emergency Stockpile Framework
  • Demand Triggers During Outbreak Response
  • Inventory Management and Allocation Strategies
  • Public Health Preparedness Initiatives
  • Future Stockpiling Priorities
Manufacturing Capacity and Supply Security Assessment
  • Global Production Footprint
  • Capacity Expansion Initiatives
  • Supply Continuity and Risk Mitigation
  • Strategic Manufacturing Partnerships
  • Long-Term Supply Resilience

Need a different cut of the data?

Request Custom Research
Frequently Asked Questions

How much is the cholera vaccines market worth?

The market valuation of the cholera vaccines is USD 118.91 million in 2027.

What is the anticipated CAGR of the cholera vaccines industry?

Cholera Vaccines Market size was around USD 110.1 million in 2026 and is slated to grow at a 9.5% CAGR from 2027 to 2036, attaining USD 272.85 million by 2036.

How are preventive immunization strategies reshaping procurement in the cholera vaccines market?

Health authorities are shifting toward routine vaccination planning, targeted campaigns, and pre-emptive stockpiling, making vaccine procurement a planned public health investment rather than an emergency-only response in endemic regions.

Why are global partnerships and production expansion becoming strategically important in the cholera vaccines market?

NGO-led campaigns, WHO elimination goals, and technology transfer initiatives are broadening procurement opportunities, improving manufacturing capacity, strengthening supply continuity, and enabling larger immunization programs across underserved and high-risk populations.

Why do Killed Oral O1 and O139 vaccines lead the cholera vaccines market?

Killed Oral O1 and O139 held a 63% market share in 2026 due to their suitability for large-scale immunization programs, with oral delivery supporting efficient deployment and broad coverage across target populations.

Why is retail pharmacy the fastest-growing distribution channel in the cholera vaccines market?

Retail pharmacy is growing fastest because it expands community-level vaccine access, offering greater convenience and supporting broader distribution beyond hospital-centered immunization pathways.

Why does North America lead the cholera vaccines market?

North America holds 39.86% share due to strong procurement systems, advanced public health infrastructure, and coordinated vaccine distribution and preparedness frameworks.

How is Asia Pacific driving fastest growth in cholera vaccines market?

Asia Pacific grows at 11.31% CAGR due to higher outbreak exposure, expanding immunization campaigns, and increasing preventive vaccination in vulnerable populations.

What are the key competitors in the cholera vaccines landscape?

Major players in the cholera vaccines market include Sanofi S.A. (France), Valneva SE (France), EuBiologics Co., Ltd. (South Korea), Bharat Biotech International Ltd. (India), Serum Institute of India Pvt. Ltd. (India), Emergent BioSolutions Inc. (United States), Incepta Vaccine Ltd. (Bangladesh), Vabiotech (Vietnam), PT Bio Farma (Persero) (Indonesia), Shantha Biotechnics Pvt. Ltd. (India).
Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →